Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR HFA versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR HFA versus FLUDROCORTISONE ACETATE.
ADVAIR HFA vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADVAIR HFA is a combination of fluticasone propionate, a corticosteroid that reduces inflammation by inhibiting multiple inflammatory cell types and mediators, and salmeterol, a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing cAMP levels.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
2 inhalations (fluticasone 230 mcg/salmeterol 21 mcg per inhalation) twice daily, approximately 12 hours apart, via oral inhalation. Maximum: 2 inhalations twice daily.
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
Fluticasone propionate: 7.8 hours (inhalation), prolonged in hepatic impairment. Salmeterol: 5.5 hours.
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Fluticasone propionate: Renal <5%, fecal (primarily as metabolites) ~90%. Salmeterol: Renal 25% (as metabolites), fecal 60%.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid/LABA Combination
Corticosteroid